Abiomed Inc.

Latest Abiomed Inc. News and Updates

  • uploads///Graph
    Company & Industry Overviews

    Inside Abiomed’s Profit Margin Expectations for Fiscal 2018

    For fiscal 2018 (ended March 31, 2018), Abiomed (ABMD) has projected that its operating margins will be in the range of 22%–24%.

    By Margaret Patrick
  • uploads///ABMD
    Company & Industry Overviews

    Examining Abiomed’s Gross Margin Trend

    In the second quarter of 2018, Abiomed’s (ABMD) cost of revenue rose YoY (year-over-year) to $29.85 million.

    By Kenneth Smith
  • uploads///stock trading monitor desk
    Consumer

    Renaissance Technologies: Analyzing Its Q3 13F

    At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies’ top five buys.

    By Rabindra Samanta
  • uploads///ABMD
    Company & Industry Overviews

    Do Analysts See Any Upside for Abiomed Stock?

    In this year’s second quarter, Abiomed’s (ABMD) net investment income rose YoY (year-over-year) to $1.67 million from $781,000.

    By Kenneth Smith
  • uploads///blood _
    Company & Industry Overviews

    Exploring Abiomed’s Latest Performance Trends

    In this series, we’ll explore Abiomed’s financials and valuation along with analysts’ views on its stock.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    What Analysts Expect for Abiomed

    Wall Street analysts estimate Abiomed (ABMD) will report 29.9% growth in revenues to ~$771.0 million in 2019 as compared to $593.7 million in 2018.

    By Mike Benson
  • uploads///hand _
    Company & Industry Overviews

    Do Abiomed’s Valuations Look Attractive?

    Abiomed’s (ABMD) revenues rose 36% YoY to ~$180 million in fiscal Q1 2019 compared to $133 million in Q1 2018.

    By Mike Benson
  • uploads///lOSSES
    Company & Industry Overviews

    S&P 500’s Top Losses: Nielsen Holdings and Facebook

    Nielsen Holdings, which is a global information, data, and measurement company, was the S&P 500’s top loss on July 26.

    By Val Kensington
  • uploads///ABMD PE MC
    Healthcare

    Analyzing ABMD, BR, and TFX Stocks

    Abiomed’s (ABMD) net income has grown at a three-year and five-year average of 95.1% and 120.4%, respectively.

    By Amanda Lawrence
  • uploads///proj pe ratio
    Consumer

    Total Returns and Sector Exposure for Growth Indexes—Continued

    The S&P 900 Growth and S&P 900 Pure Growth indexes have three-year annualized returns of 13% and 9.7%, respectively.

    By Amanda Lawrence
  • uploads///GROWTH INDEX EXPO TO IT
    Consumer

    Total Returns and Sector Exposure for Growth Indexes

    If we dig into the S&P 500 and the S&P Growth indexes, we can see that they have the highest exposure to information technology (or IT).

    By Amanda Lawrence
  • uploads///office _
    Materials

    18 Earnings Reports We’re Watching Closely Next Week

    Last big week of earnings kicks off with not a lot to show for it in the market The week of April 30 is an exciting one in terms of earnings, and here are 18 companies we will be watching closely: Monday McDonald’s Corporation (NYSE: MCD) – before the market opens – great year last […]

    By JP Gravitt
  • uploads///EW revenue
    Company & Industry Overviews

    Analyzing Edwards Lifesciences’ Recent Acquisitions

    In December 2017, Edwards Lifesciences (EW) acquired Harpoon Medical for a total consideration of $119.5 million.

    By Kenneth Smith
  • uploads///blood _
    Company & Industry Overviews

    What Analysts Recommend for Edwards Lifesciences

    Of the 22 analysts covering Edwards Lifesciences in February 2018, 17 analysts have given the stock a “buy” or a higher rating.

    By Kenneth Smith
  • uploads///MMSI revenue
    Company & Industry Overviews

    Exploring Merit Medical Systems’ Business Segments

    In 3Q17, Merit Medical Systems’ cardiovascular segment generated revenues of $172.7 million—compared to $150.5 million in 3Q16.

    By Kenneth Smith
  • uploads///doctors office checkup medical
    Company & Industry Overviews

    Merit Medical Systems: Analysts’ Ratings in February 2018

    Of the eight analysts covering Merit Medical Systems in February, four gave it a “strong buy,” three gave it a “buy,” and one gave it a “sell” rating.

    By Kenneth Smith
  • uploads///ABMD RD
    Company & Industry Overviews

    Why Abiomed’s Product Pipeline Looks Promising

    Abiomed (ABMD) is strategically focused on the market penetration of the company’s family of Impella heart pumps.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Edwards Lifesciences: Analyst Recommendations in November

    In 3Q17, Edwards Lifesciences (EW) reported adjusted sales of ~$838 million, which is an underlying growth of ~13% on a YoY basis. This performance was driven by double-digit organic growth.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    HVAD Expected to Expand Medtronic’s Presence in LVAD Segment

    On September 27, 2017, the FDA approved Medtronic’s HVAD (HeartWare ventricular assist device) system as a destination therapy for advanced heart failure patients.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Medtronic Focused on Efficacy and Safety of LVAD Offerings

    Medtronic (MDT) aims to leverage its expertise in implantable pump and electronics segments to further improve Heartware’s LVAD (left ventricular assist device) product portfolio.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Understanding Abiomed’s Changing Payment Structure Plans for Impella

    Abiomed (ABMD) reported a ~100% reorder rate in fiscal 4Q17, amounting to around $103.3 million, which was 34% higher on a YoY basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Where Abiomed Plans to Expand Impella CP’s Label

    About 40% of patients succumb to heart failure within five years. Abiomed believes that it is reperfusion injuries that cause these problems.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Abiomed Expects to Benefit from Impella in Cardiogenic Shock

    On March 23, 2015, the FDA approved Abiomed’s Impella 2.5 heart pump as a temporary ventricular support device.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Behind Abiomed’s Plans to Create a Greater Awareness of Impella

    To target patients across communities, Abiomed (ABMD) has been developing a hub-and-spoke model with hospitals.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Abiomed Expects to Expand Its Presence in This Space

    Abiomed is primarily focused on the growth opportunity in the protected PCI area, a procedure that is applicable for patients with coronary artery disease.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Abiomed Aims to Expand Impella RP’s Penetration Going Forward

    In March 2017, Abiomed (ABMD) submitted premarket approval (or PMA) to the FDA for its Impella RP device far ahead of schedule.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Abiomed in 2017: The Analysts’ View

    For the quarter ending March 31, 2017, Abiomed (ABMD) reported revenues close to $124.7 million, which represents a YoY growth of about 30%.

    By Margaret Patrick
  • uploads///thoratec integration
    Company & Industry Overviews

    Thoratec Acquisition: The Impact on St. Jude’s Growth Potential

    On October 8, 2015, St. Jude Medical (STJ) completed the acquisition of Thoratec for $3.3 billion in net cash consideration. It’s St. Jude’s largest acquisition ever.

    By Sarah Collins
  • uploads///hf
    Company & Industry Overviews

    St. Jude’s Heart Failure Segment: Performance and Opportunities

    St. Jude Medical’s (STJ) heart failure therapy area generated sales of $4 billion and witnessed mid-single-digit growth in 2015.

    By Sarah Collins
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Nuvasive Traded above Its 100-Day Moving Average

    Nuvasive (NUVA) gained 1.3% on October 12, 2015. The stock went up on the news that the FDA gave clearance for NUVA’s cervical corpectomy cage.

    By Peter Neil
  • Market Realist Logo

    © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.